ABL1 and Aortic dissection: Imatinib and erlotinib are 2 TKIs with different target receptors (c-abl and epidermal growth factor receptor, respectively) that have shown the capacity to attenuate experimental aneurysm growth in the murine AngII-induced aortic dissection model (20, 21).